Combination immunotherapy with ipilimumab and nivolumab in patients with rare gynaecological malignancies.
Oliver Klein, Damien Kee, Bo Gao, Markman Ben, Linda R Mileshkin, Clare L Scott, Yeojeong So, Richelle Linklater, Andreas Behren, Jodie Palmer, Matteo S Carlino, Jonathan S Cebon
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
6091 Background: Up to 50% of gynecological cancers are considered rare. The outcome of these patients (pts) is poor given a lack of scientific and clinical knowledge. Immunotherapy using single agent anti- PD-1/PD-L1 treatment (tx) has shown only modest activity in patients with common gynecological malignancies, such as high grade serous ovarian cancer (ca) and microsatellite stable endometrial ca. Combined CTLA-4/PD-1 blockade using ipilimumab (ipi) and nivolumab (nivo) has demonstrated superior efficacy compared to single agent anti-PD-1 therapy in pts with advanced melanoma and renal cell ca. To date, no trials have been undertaken with ipi/nivo in patients with rare gynecological mali..View full abstract
Australian Federal Department of Health